Skip to content

The influence of peroperative dobutamine infusion on the blood flow of the DIEP-flap

The influence of peroperative dobutamine infusion on the blood flow of the DIEP-flap - Influence of dobutamine on blood flow

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON38526
Enrollment
60
Registered
2013-10-15
Start date
2013-11-18
Completion date
Unknown
Last updated
2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast reconstruction with own tissue DIEP-flap reconstruction

Interventions

1. Dobutamine 5microgram/kg/min peroperative, 18hours postoperative 0.9% NaCl infusion 2. Dobtuamine 5microgram/kg/min until 18hours postoperative 3. 0.9% NaCl infusion both per- and 18hours postoper

Sponsors

Orbis Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - women - age between 30 and 65 years old - breast carcinoma in the history - mastectomy in the history - planned secondary reconstruction by means of a DIEP-flap

Exclusion criteria

Exclusion criteria: - cardiac history (i.e. atrial fibrillation) - clotting disorders (deep venous thrombosis or pulmonary embolus in the history) - smoking - allergic reaction to dobutamine or bisulfate

Design outcomes

Primary

MeasureTime frame
Increase in microcirculatory blood flow after dobutamine infusion and measured by means of laser Doppler flowmetry.

Secondary

MeasureTime frame
1. Is the incidence of partial or total flap necrosis lower after peroperative intravenous dobutamine infusion as compared to placebo [clinical judgement: the amount of visible necrotic (black) tissue, measured and calculated as percentage of the total flap]? 2. Is the incidence of fat necrosis lower after peroperative intravenous dobutamine infusion as compared to placebo (postoperative ultrasound)? 3. Is the incidence of partial or total flap necrosis and fat necrosis lower when dobutamine is given 18 hours post-operative as compared to peroperative? 4. How often has the escape been used to keep the blood pressure at level? 5. Quality of life (measured by means of a questionnaire sent after 2 weeks, 6 weeks and 3 months) Other study parameters which might intervene with the main study endpoints are body weight, chemotherapy, radiation therapy, previously abdominal surgery, diabetes and smoking.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)